About Icon Plc
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. Its services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. The Company's information systems offerings include ICONIK, Firecrest, ADDPLAN, AptivAdvantage and Aptiv Insite. It conducts various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial. The Company offers clinical development services, including investigator recruitment, patient registries, outcomes research, clinical data management, immunoassay development and others.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Laboratories & Research
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: ICLR
- Previous Close: $85.68
- 50 Day Moving Average: $81.90
- 200 Day Moving Average: $78.28
- 52-Week Range: $62.31 - $88.90
- Trailing P/E Ratio: 19.20
- Foreward P/E Ratio: 16.70
- P/E Growth: 1.40
- Market Cap: $4.78B
- Outstanding Shares: 55,827,000
- Beta: 0.63
- Net Margins: 15.60%
- Return on Equity: 29.47%
- Return on Assets: 14.43%
Companies Related to Icon Plc:
- Debt-to-Equity Ratio: 0.40%
- Current Ratio: 2.20%
- Quick Ratio: 2.20%
What is Icon Plc's stock symbol?
Icon Plc trades on the NASDAQ under the ticker symbol "ICLR."
Where is Icon Plc's stock going? Where will Icon Plc's stock price be in 2017?
8 analysts have issued 12 month target prices for Icon Plc's stock. Their forecasts range from $59.00 to $90.00. On average, they expect Icon Plc's share price to reach $81.50 in the next twelve months.
When will Icon Plc announce their earnings?
Icon Plc is scheduled to release their next quarterly earnings announcement on Tuesday, February, 21st 2017.
What are analysts saying about Icon Plc stock?
Here are some recent quotes from research analysts about Icon Plc stock:
According to Zacks Investment Research, "ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide. " (1/17/2017)
Jefferies Group LLC analysts commented, "Focus on operational improvement and tech/analytics enablement is driving new business wins and development of a growing tranche of mid-tier clients. Management is confident in its guidance outlook, though client mix is somewhat less clear. Management is eyeing M&A for some capital deployment, while also expecting to re-authorize share repurchase at its 2016 AGM. Key Topics: 1) win rate improving in key therapeutic areas, driven by differentiated tech, 2) half dozen sizable strategic partnerships, 3) PFE revenue continuing to fade, 4) $400M share repurchase, 5) close to a couple of deals." Tech Suite Driving Differentiation. Firecrest, ADDPLAN, and ICONIK are ICON’s tech platforms aimed at bottlenecks and lower hanging fruit in trial efficiency. Issues of the 2000s like faster database lock at the end of a trial largely have been fixed by use of EDC systems during trials. The refractory issues in trials today are patient recruitment, site education/training/adherence to protocol, and the labor intensive nature of monitoring (think auditing") clinical trial data. ICON owns the industry standard adaptive trial software. Firecrest augments and replaces costly in person meetings, travel, and investigator errors. ICONIK essentially serves as air traffic control on trials, enabling assessment of potentially risky data patterns at the patient, site, and trial level. ICON highlighted that increasing win rates specifically in CNS from a disease-specific analytical package. It is building a second one in oncology." (5/11/2016)
Who owns Icon Plc stock?
Icon Plc's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (2.72%), William Blair Investment Management LLC (1.80%), Fiera Capital Corp (1.30%), Brown Capital Management LLC (1.05%), Alyeska Investment Group L.P. (0.70%) and Marshall Wace LLP (0.70%).
Who sold Icon Plc stock? Who is selling Icon Plc stock?
Icon Plc's stock was sold by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Fiera Capital Corp, Castleark Management LLC, Loomis Sayles & Co. L P, Ranger Investment Management L.P., Clark Capital Management Group Inc., Two Sigma Investments LP and Foresters Investment Management Company Inc..
Who bought Icon Plc stock? Who is buying Icon Plc stock?
Icon Plc's stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace LLP, Russell Investments Group Ltd., Thompson Siegel & Walmsley LLC, Renaissance Technologies LLC, Capstone Investment Advisors LLC, Brown Capital Management LLC and Alyeska Investment Group L.P..
How do I buy Icon Plc stock?
Shares of Icon Plc can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Icon Plc stock cost?
One share of Icon Plc stock can currently be purchased for approximately $85.68.